Find Clinical Trial

INES – Phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with oestrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer.


← Back
Study Phase Phase 1
Therapeutic Area Oncology
Active Substance LUCITANIB
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active Substance CodeS080881
Protocol CodeCL1-80881-002
EudraCT Code2013-001520-19
ISRCTN CodeISRCTN23201971


Documents and links

Results summary READ MORE




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2017 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
More information

Report a side-effect with a drug.